Reaction
Injection Site Papule reporting signals
As of the last recalculation, Injection Site Papule appears in 4,463 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB (PRR 70.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab | 3,181 | 70.5 | 70.8 |
| Risankizumab-Rzaa | 342 | 21.0 | 21.1 |
| Pegvaliase-Pqpz | 22 | 12.5 | 12.6 |
| Mesalamine | 101 | 8.6 | 8.6 |
| Mercaptopurine | 25 | 6.8 | 6.8 |
| Multivitamin | 67 | 6.3 | 6.3 |
| Onabotulinumtoxina | 74 | 4.5 | 4.5 |
| Folic Acid | 215 | 4.2 | 4.2 |
| Methotrexate | 313 | 3.7 | 3.7 |
| Botulinum Toxin Type A | 8 | 3.0 | 3.0 |
| Nemolizumab-Ilto | 8 | 2.9 | 2.9 |
| Cabotegravir | 4 | 2.3 | 2.3 |
| Etanercept | 251 | 2.0 | 2.0 |
| Galcanezumab-Gnlm | 12 | 1.8 | 1.8 |
| Fremanezumab-Vfrm | 4 | 1.6 | 1.6 |
| Ixekizumab | 12 | 1.5 | 1.5 |
| Romosozumab-Aqqg | 4 | 1.4 | 1.4 |
| Erenumab-Aooe | 14 | 1.2 | 1.2 |
| Palivizumab | 3 | 0.9 | 0.9 |
| Evolocumab | 31 | 0.9 | 0.9 |
| Abaloparatide | 5 | 0.8 | 0.8 |